| 2.8511 0.061 (2.19%) | 11-28 13:34 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.58 | 1-year : | 4.18 |
| Resists | First : | 3.06 | Second : | 3.58 |
| Pivot price | 2.44  |
|||
| Supports | First : | 2.37 | Second : | 1.95 |
| MAs | MA(5) : | 2.83 |
MA(20) : | 2.38 |
| MA(100) : | 3.21 |
MA(250) : | 4.03 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 81.3 |
D(3) : | 79.8 |
| RSI | RSI(14): 60.7 |
|||
| 52-week | High : | 7.17 | Low : | 1.95 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ TXMD ] has closed below upper band by 21.4%. Bollinger Bands are 126.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.88 - 2.9 | 2.9 - 2.91 |
| Low: | 2.75 - 2.77 | 2.77 - 2.78 |
| Close: | 2.76 - 2.79 | 2.79 - 2.81 |
TherapeuticsMD, Inc. operates as a women's healthcare company in the United States. The company offers IMVEXXY for the treatment of moderate-to-severe dyspareunia; BIJUVA, a bio-identical hormone therapy combination of 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms; and ANNOVERA, a ring-shaped contraceptive vaginal system. Its preclinical projects include the development of TX-005HR, a progesterone-alone transdermal cream; TX-006HR, an estradiol and progesterone transdermal cream; TX-007HR and TX-008HR, which are transdermal patch product candidates; and TX-009HR, an oral progesterone and estradiol formulation. It also manufactures and distributes branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands. The company sells its prescription pharmaceutical products and prenatal vitamin products to wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
Fri, 24 Nov 2023
Bio-Identical Hormone Replacement Market To Reach USD 61.5 ... - GlobeNewswire
Wed, 22 Nov 2023
TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch
Fri, 17 Nov 2023
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch
Wed, 15 Nov 2023
TherapeuticsMD: Q3 Earnings Snapshot - The Washington Post - The Washington Post
Mon, 30 Oct 2023
TherapeuticsMD Inc (TXMD) Stock: Do Analysts Think You Should Hold? - InvestorsObserver
Thu, 26 Oct 2023
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers—Specialty & Generic
|
|
| Shares Out | 0 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 7.08e+006 (%) |
| Held by Institutions | 8.1 (%) |
| Shares Short | 104 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 5.16e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 98.4 % |
| Operating Margin | 3 % |
| Return on Assets (ttm) | 345.2 % |
| Return on Equity (ttm) | 34.5 % |
| Qtrly Rev. Growth | 6.937e+007 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 4.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -141 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 1.24 |
| Dividend | 0 |
| Forward Dividend | 248470 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|